CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 79 filers reported holding CYTOSORBENTS CORP in Q2 2022. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,800 | -47.6% | 10,000 | 0.0% | 0.02% | -40.7% |
| Q2 2023 | $35,900 | +6.5% | 10,000 | 0.0% | 0.03% | +3.8% |
| Q1 2023 | $33,700 | +117.4% | 10,000 | 0.0% | 0.03% | +116.7% |
| Q4 2022 | $15,500 | +10.7% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $14,000 | -36.4% | 10,000 | 0.0% | 0.01% | -33.3% |
| Q2 2022 | $22,000 | -31.2% | 10,000 | 0.0% | 0.02% | -14.3% |
| Q1 2022 | $32,000 | -23.8% | 10,000 | 0.0% | 0.02% | -22.2% |
| Q4 2021 | $42,000 | -48.1% | 10,000 | 0.0% | 0.03% | -55.0% |
| Q3 2021 | $81,000 | +6.6% | 10,000 | 0.0% | 0.06% | +7.1% |
| Q2 2021 | $76,000 | -12.6% | 10,000 | 0.0% | 0.06% | -18.8% |
| Q1 2021 | $87,000 | +8.8% | 10,000 | 0.0% | 0.07% | 0.0% |
| Q4 2020 | $80,000 | 0.0% | 10,000 | 0.0% | 0.07% | -4.2% |
| Q3 2020 | $80,000 | -19.2% | 10,000 | 0.0% | 0.07% | -33.9% |
| Q2 2020 | $99,000 | +28.6% | 10,000 | 0.0% | 0.11% | +17.2% |
| Q1 2020 | $77,000 | +102.6% | 10,000 | 0.0% | 0.09% | +126.8% |
| Q4 2019 | $38,000 | – | 10,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sargent Investment Group, LLC | 964,141 | $7,829,000 | 1.90% |
| Skylands Capital, LLC | 1,837,541 | $14,921,000 | 1.84% |
| CM Management, LLC | 175,000 | $1,421,000 | 1.06% |
| Soleus Capital Management, L.P. | 800,000 | $6,496,000 | 1.01% |
| Avenir Corp | 1,395,385 | $11,331,000 | 0.95% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 185,000 | $1,502,000 | 0.55% |
| Winning Points Advisors, LLC | 86,200 | $701,000 | 0.51% |
| Granahan Investment Management | 1,154,561 | $9,375,000 | 0.18% |
| SECTORAL ASSET MANAGEMENT INC | 244,660 | $1,987,000 | 0.16% |
| Redmile Group, LLC | 1,044,434 | $8,481,000 | 0.15% |